EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 303 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Cancer Does Not Affect All People Equally: An Expert Q&A on... June 30, 2020 Girl Whose Insides Were Sucked From Her Body While Sitting On... June 14, 2019 High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults... June 15, 2021 Inseparable Couples Dies 33 Hours Apart After 68 Years Of Marriage:... December 5, 2019 Load more HOT NEWS Pembrolizumab Continues to Demonstrate Durable Efficacy with No New Safety Signals... Opportunity and mentorship: Our new PhD programme aiming to open-up academia... Coronavirus reports – Part 9: “I am very relieved but I... Poziotinib Shows Promising Antitumour Activity in Patients with HER2 Exon 20...
